Two trials examined olanzapine and found no difference in the primary outcome ( response to treatment ) and most other efficacy-related outcomes but it was associated with more weight gain than monotherapy with antidepressants .
There were also some beneficial effects of quetiapine in terms of anxiety or depressive symptoms .
BACKGROUND Obsessive compulsive disorder ( OCD ) is a psychiatric disorder which has been shown to affect 2 to 3.5 % of people during their lifetimes .
Inadequate response occurs in 40 % to 60 % of people that are prescribed first line pharmaceutical treatments ( selective serotonin reuptake inhibitors ( SSRIs ) ) .
To date not much is known about the efficacy and adverse effects of second-generation antipsychotic drugs ( SGAs ) in people suffering from OCD .
OBJECTIVES To evaluate the effects of SGAs ( monotherapy or add on ) compared with placebo or other forms of pharmaceutical treatment for people with OCD .
Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients.
OBJECTIVE To assess the efficacy of quetiapine addition to citalopram in treatment-naive or medication-free obsessive-compulsive disorder ( OCD ) patients . METHOD Seventy-six patients who met DSM-IV criteria for OCD and who were drug-free or drug-naive at entry were r and omly assigned in a 10-week , double-blind trial with citalopram ( 60 mg/day ) plus quetiapine ( 300 - 450 mg/day ) or placebo ;  treatment-refractory OCD patients were excluded . Of the 76 eligible patients , 66 patients completed the trial-31 in the quetiapine and 35 in the placebo group . The change from baseline to endpoint on the total Yale-Brown Obsessive Compulsive Scale ( YBOCS ) and the response to treatment in the quetiapine addition compared with the placebo addition group were the primary outcome measures . Response was defined as a 35 % or greater reduction on the YBOCS and a Clinical Global Impressions-Improvement ( CGI-I ) score at endpoint of 1 or 2 . The study was conducted from November 2003 to June 2005 at the University Medical Centre Utrecht , The Netherl and s. RESULTS As measured by the mean reduction in YBOCS scores following an intent-to-treat , last-observation-carried-forward analysis , quetiapine addition ( 11.9 ) was significantly superior to placebo ( 7.8 ; p = .009 ) . Quetiapine addition was also significantly superior to placebo on the CGI-I scale , with a mean + /- SD CGI-I score of 2.1 + /- 1.3 versus 1.4 + /- 1.2 , respectively ( p = .023 ) . Quetiapine addition ( N = 22 , 69 % ) was also associated with a significantly greater number of patients responding to treatment compared with placebo addition ( N = 15 , 41 % ; p = .019 ) . More patients receiving quetiapine ( N = 8) than placebo ( N = 2 ; NS ) discontinued treatment due to adverse events . CONCLUSIONS The combination of quetiapine and citalopram was more effective than citalopram alone in reducing OCD symptoms in treatment-naive or medication-free OCD patients . TRIAL REGISTRATION www.trialregister.nl Identifier NTR116
Two trials examined olanzapine and found no difference in the primary outcome ( response to treatment ) and most other efficacy-related outcomes but it was associated with more weight gain than monotherapy with antidepressants .
There were also some beneficial effects of quetiapine in terms of anxiety or depressive symptoms .
BACKGROUND Obsessive compulsive disorder ( OCD ) is a psychiatric disorder which has been shown to affect 2 to 3.5 % of people during their lifetimes .
Inadequate response occurs in 40 % to 60 % of people that are prescribed first line pharmaceutical treatments ( selective serotonin reuptake inhibitors ( SSRIs ) ) .
To date not much is known about the efficacy and adverse effects of second-generation antipsychotic drugs ( SGAs ) in people suffering from OCD .
OBJECTIVES To evaluate the effects of SGAs ( monotherapy or add on ) compared with placebo or other forms of pharmaceutical treatment for people with OCD .